Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.38 |
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
| ▸ | ESRRA | P11474 | 2/20 | 0.38 |
| ▸ | ESRRB | O95718 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30783550 | 1.00 | AXL (0.46) | AXLGLO1CA12CA1CA2 | |
| SCHEMBL30783555 | 1.00 | AXL (0.46) | AXLGLO1CA12CA1CA2 | |
| SCHEMBL29032220 | 0.92 | AXL (0.41) | AXLGLO1CA12CA1CA2 | |
| SCHEMBL31179009 | 0.75 | ALDH1A1 (0.46) | AXLCA12CA1CA2CA7 | |
| SCHEMBL30783551 | 0.75 | GLO1 (0.49) | GLO1CA12CA1CA2CA7 | |
| SCHEMBL28799653 | 0.75 | ESR2 (0.38) | ESR2ESR1ESRRAESRRBALDH1A1 | |
| SCHEMBL6583934 | 0.75 | GLO1 (0.49) | GLO1CA12CA1CA2CA7 | |
| SCHEMBL6583568 | 0.75 | ESR2 (0.40) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2520818 | 0.75 | — | — | |
| SCHEMBL497472 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259875-A1 | Amine derivatives | BAYER HEALTHCARE AG (DE) | 2004-12-23 | — | — | US | disclosed |
| EP-1414788-A1 | NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS | Bayer HealthCare AG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003014064-A1 | NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259875-A1 | Amine derivatives | AVPR1A, GRIN1, OPRL1 | AXL 1139/4885GLO1 2844/4885CA12 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.